2015
DOI: 10.3917/recsoc.214.0141
|View full text |Cite
|
Sign up to set email alerts
|

Entretien avec Anne-Marie Fekete

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2016
2016
2016
2016

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…In recent years, human platelet lysate (hPL) has been proposed as a substitute for FBS in MSC production [23,24]. In addition to lacking the risk of xenogeneic immune rejection or zoonosis transmission associated with FBS, hPL can be produced under good manufacturing practices at much lower costs than FBS [25,26].…”
Section: Introductionmentioning
confidence: 99%
“…In recent years, human platelet lysate (hPL) has been proposed as a substitute for FBS in MSC production [23,24]. In addition to lacking the risk of xenogeneic immune rejection or zoonosis transmission associated with FBS, hPL can be produced under good manufacturing practices at much lower costs than FBS [25,26].…”
Section: Introductionmentioning
confidence: 99%